Tier 1 — highest

Clinical evidence for low-molecular-weight collagen peptides in tendon and ligament tears: a systematic review with narrative synthesis

Luca Latini, Francesco Porta, Nicolò Vitale, Florentin Ananu Vreju, Emilio Filippucci
Frontiers in Medicine 2026 13:1891011

Bibliography

PubMed
PMID 42666580
PubMed Central
PMC13523136
Funding
The authors declared that no financial support was received for the work and/or its publication.
Competing interests
Luca Latini was employed by Centro Medico e Fisioterapia 'Salute e Benessere' and Nicolò Vitale by Centro Medicina Riabilitativa 'CMR'; remaining authors declared no commercial or financial relationships that could be construed as conflicts.

Study snapshot

DesignSystematic review with narrative synthesis using PubMed and Scopus searches through 17 March 2026
ModelHuman tendon or ligament tears, postoperative repair/reconstruction, and closely related tendon/ligament conditions
Sample6 studies included
InterventionOral or injectable hydrolyzed/low-molecular-weight collagen peptide preparations; several oral interventions were multicomponent and formulations/routes varied substantially.
DurationReview search through 17 March 2026; included-study follow-up varied
EndpointsPain; Function; Analgesic use; Imaging outcomes; Structural healing; Reinjury/return-to-sport evidence

What the study showed, in plain terms

This 2026 systematic review found only six relevant human studies for tendon and ligament tears or closely related conditions. Signals were cautiously favorable for pain or function, but the evidence was sparse, heterogeneous and often confounded by multicomponent products.

Key findings

Three studies provided direct tear/post-surgical evidence and three were contextual. Most oral interventions were multicomponent, only one direct tear study used a clearly defined low-molecular-weight peptide formulation, and the authors concluded that certainty remains low.

What this study can and cannot tell us

Very small evidence base; heterogeneous routes and formulations; multicomponent oral products; limited blinding/placebo control; short follow-up and patient-reported endpoints; review used a focused two-database strategy and narrative rather than quantitative synthesis.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified